RecruitingRecruiting
HPC Offered for PRESERVE Expansion
NCT07145411 · Ossium Health, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product
Eligibility criteria
Inclusion Criteria:
Patients aged 12-80 may be eligible\* to receive bone marrow for transplantation through the Ossium HOPE Program if:
Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks
Study design
Enrollment target: 10 participants
Age groups: child, adult, older_adult
Timeline
Starts: 2024-06-27
Estimated completion: 2029-08
Last updated: 2025-08-28
Interventions
Other: Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
Primary outcomes
- • Neutrophil engraftment (28 days)
Sponsor
Ossium Health, Inc. · industry
Contacts & investigators
ContactPreethi Prasad, Senior Director Clinical Operations · contact · preethi.prasad@ossiumhealth.com · 415-513-5535
All locations (4)
University of Alabama, BirminghamRecruiting
Birmingham, Alabama, United States
Henry Ford HealthRecruiting
Detroit, Michigan, United States
The Ohio State University Medical CenterRecruiting
Columbus, Ohio, United States
Tristar Centennial Medical CenterRecruiting
Nashville, Tennessee, United States